Mei Pharma, INC Form 4 insider transactions

Lite Strategy, Inc. Director James P. Flynn acquired 25,000 common shares for $0.8555 per share, increasing his beneficial ownership.

Lite Strategy's CEO, CFO, and Secretary, Justin J. File, was granted 455,000 stock options as employment compensation, vesting over 34 months.

Alexander Schornstein, a director and former 10% owner of Lite Strategy, Inc., sold 690,611 shares of common stock for approximately $1.37 per share.

Lite Strategy, Inc. Director James P Flynn acquired 70,000 shares of common stock at an average price of $1.3957 per share.

Lite Strategy, Inc.'s CEO, Justin J. File, filed an amended Form 4 to correct the number of stock options granted, now accurately reporting 180,000 options.

Lite Strategy Director James P. Flynn acquired 12,100 shares of common stock in a pre-planned transaction.

Lite Strategy, Inc. Director Nicholas Glover was granted 55,000 stock options as part of customary annual non-employee director compensation.

Frederick W. Driscoll, a director at Lite Strategy, Inc., was granted 55,000 stock options with an exercise price of $2.02 as part of his annual compensation.

Lite Strategy, Inc. Director Joshua Riezman was granted 65,000 stock options with an exercise price of $2.02 as compensation for his board service.

Lite Strategy, Inc. Director James P. Flynn received a customary annual grant of 55,000 stock options with an exercise price of $2.02.

Lite Strategy, Inc.'s CEO, CFO, and Secretary, Justin J. File, acquired 635,000 stock options as employment compensation, vesting over 36 months.

Lite Strategy, Inc. Director Charles Benjamin Lee was granted 10,000 stock options with an exercise price of $2.56, vesting over 36 months.

Lite Strategy Director James P Flynn acquired 10,000 shares of common stock at a weighted-average price of $2.543 per share, increasing his beneficial ownership to 17,900 shares.

MEI Pharma, Inc. director Joshua Riezman was granted 10,000 stock options with an exercise price of $5.19, vesting monthly over three years.

MEI Pharma, Inc. Director Steven D. Wood was granted 20,000 stock options with an exercise price of $3.07, effective July 15, 2025.

MEI Pharma, Inc. Director Thomas C. Reynolds was granted 20,000 stock options with an exercise price of $3.07, exercisable from July 15, 2025, and expiring on July 15, 2035.

MEI Pharma, Inc. Director Nicholas Glover was granted 20,000 stock options with an exercise price of $3.07, exercisable immediately and expiring in 2035.

MEI Pharma, Inc. Director James P. Flynn was granted 20,000 stock options with an exercise price of $3.07, exercisable immediately.

MEI Pharma, Inc.'s Secretary, Acting CEO & CFO, Justin J. File, was granted 20,000 stock options as part of a customary annual executive compensation package.

Frederick W. Driscoll, a Director at MEI Pharma, Inc., acquired 20,000 stock options with a $3.07 exercise price, while the company noted the customary annual grant to non-employee directors was not made for the fiscal year ended June 30, 2025.

Director Steven D. Wood reports purchasing shares of MEI Pharma and indirectly disposing of shares.

Director James P. Flynn of MEI Pharma, Inc. reports purchasing 7,900 shares of common stock at a weighted-average price of $3.1621 on May 16, 2024.